Novartis’ subsidiary Sandoz has secured approval from the European Commission (EC) for its biosimilar product Zessly (infliximab) to treat gastroenterological, rheumatological and dermatological diseases.

Zessly is designed to inhibit the activity of tumour necrosis factor (TNF)-alpha in some autoimmune diseases, for which excess TNF-alpha activity may be harmful or lead to their onset.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This inhibition is intended to help in addressing an underlying cause of inflammation.

The approval covers use of Zessly for the treatment of all indications of the reference medicine, including Crohn’s disease, rheumatoid arthritis, ulcerative colitis, plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.

Sandoz CEO Richard Francis said: “The European Commission approval for Zessly is a key milestone in bringing this important medicine to appropriate patients.

“The European Commission approval for Zessly is a key milestone in bringing this important medicine to appropriate patients.”

“Biosimilars, such as Zessly, help to address a significant unmet need for earlier patient access to biologic medicines and are at the heart of our Sandoz commitment to improving and extending lives.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The regulatory agency’s decision is based on a comprehensive development programme that included analytical, preclinical and clinical data.

These findings are reported to have validated that the safety, efficacy and quality of Zessly are similar to that of the reference medicine.

The EC also reviewed results from the Phase III confirmatory study which met its primary endpoint of equivalent efficacy in patients suffering from rheumatoid arthritis.

Zessly is Sandoz’s sixth biosimilar medicine to gain approval, and expands its current portfolio of Omnitrope, Binocrit, Zarzio, Erelzi and Rixathon.

The company is planning for commercial launch of multiple oncology and immunology products by 2020.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact